See more : Financial Strategies Acquisition Corp. (FXCOW) Income Statement Analysis – Financial Results
Complete financial analysis of Codiak BioSciences, Inc. (CDAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codiak BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- U-Neuron Biomedical Inc (6973.TWO) Income Statement Analysis – Financial Results
- Tiger Brands Limited (TBLMY) Income Statement Analysis – Financial Results
- FinVolution Group (FINV) Income Statement Analysis – Financial Results
- RTS Oil Holdings, Inc. (RTSO) Income Statement Analysis – Financial Results
- Thermo Fisher Scientific Inc. (TN8.DE) Income Statement Analysis – Financial Results
Codiak BioSciences, Inc. (CDAK)
About Codiak BioSciences, Inc.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 22.94M | 2.92M | 388.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 22.94M | 2.92M | 388.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 64.86M | 73.98M | 59.50M | 36.54M |
| General & Administrative | 27.63M | 19.85M | 21.04M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.63M | 19.85M | 21.04M | 9.90M |
| Other Expenses | 0.00 | 906.00K | 992.00K | 0.00 |
| Operating Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Cost & Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Interest Income | 22.00K | 253.00K | 1.50M | 1.36M |
| Interest Expense | 2.70M | 1.91M | 300.00K | 0.00 |
| Depreciation & Amortization | 6.42M | 1.16M | 5.26M | 1.73M |
| EBITDA | -61.33M | -89.76M | -74.89M | -42.82M |
| EBITDA Ratio | -267.39% | -3,079.21% | -19,301.03% | 0.00% |
| Operating Income | -69.55M | -90.92M | -80.15M | -46.44M |
| Operating Income Ratio | -303.24% | -3,118.97% | -20,657.73% | 0.00% |
| Total Other Income/Expenses | 32.39M | -747.00K | 2.19M | 1.90M |
| Income Before Tax | -37.16M | -91.67M | -77.96M | -44.54M |
| Income Before Tax Ratio | -162.01% | -3,144.60% | -20,092.78% | 0.00% |
| Income Tax Expense | 4.48M | -2.73M | 1.29M | 1.90M |
| Net Income | -41.63M | -88.93M | -79.25M | -44.54M |
| Net Income Ratio | -181.53% | -3,050.81% | -20,425.77% | 0.00% |
| EPS | -1.91 | -14.04 | -6.03 | -3.40 |
| EPS Diluted | -1.91 | -14.04 | -6.03 | -3.40 |
| Weighted Avg Shares Out | 21.79M | 6.33M | 13.13M | 13.11M |
| Weighted Avg Shares Out (Dil) | 21.79M | 6.33M | 13.13M | 13.11M |
Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors
CDAK Stock: Over 30% Increase Intraday Explanation
Data from Codiak's exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology
Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways
Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters' Option
Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock
Source: https://incomestatements.info
Category: Stock Reports